Pharmact Pharmaceuticals

Pharmact Pharmaceuticals is a Germany-based subsidiary within the Pharmact Group focused on developing and industrializing D016, a proprietary biotechnological enzyme therapy being advanced under the BELACT project. The company states that D016 is a first-in-class recombinant hyaluronidase-based therapeutic intended to address the underlying vascular pathology of familial hypercholesterolaemia and arteriosclerosis, with broader ambitions in cardiovascular and neurodegenerative disease. Pharmact Pharmaceuticals is responsible for regulatory coordination, production, and worldwide logistics for the active ingredient, while the broader group manages intellectual property and licensing. Public materials describe positive preclinical proof-of-concept work, GMP manufacturing preparation, toxicology planning, and regulatory interactions with European authorities, indicating that the lead program remains in the preclinical-to-clinical-entry transition. The company appears to operate as an integrated early-stage biotech/pharma developer rather than a commercial-stage therapeutics company.